An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials With B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Ublituximab (Primary) ; Umbralisib (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Expanded access
- Sponsors TG Therapeutics Inc
- 07 Aug 2018 According to TG Therapeutics Inc media release, data from the trial presented at the 54th Annual Meeting of the American Society of Clinical Oncology and at the 23rd Congress of the EHA.
- 01 Jun 2018 According to TG Therapeutics Inc media release, data from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association.
- 04 Jul 2017 New trial record